AGM 2019 Agenda

Find below the final agenda for the MPE Annual General Meeting 2019.

Friday, 15 March 2019

13:00 – 15:00	Check-in and registration Lunch at the hotel restaurant “Bistro”
15:00 – 15:10	Welcome & Introductions Hans Scheurer – President MPE Ananda Plate – CEO MPE
15:10 – 16.10	Myeloma Treatment Updates Chair: Riikka-Leena Manninen, MPE Board Member Treatment of newly diagnosed myeloma Role of maintenance treatment New and upcoming treatments for NDMM Updates on treatment of relapsed myeloma New and upcoming treatments for relapsed MM Update on related conditions (myeloma, AL amyloidosis etc) Speaker: Prof. Heinz Ludwig, Wilhelminen Cancer Research Institute, Austria
16:10 – 17:00	Spotlight on MPE scholarship programme Chair: Kate Morgan, MPE & Ana Vallejo, MPE Myeloma UK (UK) – Research Capacity Building Workshops, Jayne Galinsky Blodkreftforeningen (Norway) – Workshop on patient involvement in myeloma research, Jacob Hygen Kraujas (Lithuania) – Myeloma infoday and the book “Sexuality and oncological diseases”, Aistė Strelčiūnė Blodcancerförbundet Sweden (Sweden) – Workshop on combination therapy in myeloma, Lise-Lott Eriksson Borka (Macedonia) – Myeloma campaign “Let’s make changes”, Biba Dodeva
17:00 – 17:15	Coffee break
17:15 – 19:00	Plenary Workshop AL Amyloidosis Chair: Ananda Plate and Hans Scheurer, MPE Introduction to AL amyloidosis (20 min) Speaker: Dr Moshe Gatt, Israel AL amyloidosis from a patient advocates view (10 min.) Speaker: Daniel Drimer, Amyloidosis Israel Challenges of diagnosing myeloma from the patient advocates view (10 min.)Speaker: Varda Shoham, Myeloma Israel Workshop (40 min. team work in small groups and 20 minutes for discussion/feedback) How can the AL amyloidosis and myeloma community collaborate to help build a stronger AL amyloidosis community in Europe? What does the picture of diagnosing AL amyloidosis and myeloma look like in your country? How can we tackle the issue of late diagnosis of AL amyloidosis and myeloma at national level? What can MPE do to tackle the issue of late diagnosis of AL amyloidosis and myeloma at a Europe level?
20:00 – 22:00	Dinner (Hotel restaurant “Bistro”)

Saturday, 16 March 2019

09:00 – 10:00	Surrogate end-points and biomarkers in myeloma and AL amyloidosis Chair: Ron Dloomy, MPE Board Member Minimal residual disease in myeloma and AL amyloidosis Biomarkers in myeloma and AL amyloidosis Regulatory challenges associated with these and getting new medicines approved Speaker: Dr. Moshe Gatt, Israel
10:00 – 10:15	Coffee break
10:15 – 11:15	The role of CAR-T – Room: Sapporo/Harrare Chair: Roman Slomkowski, MPE Board Member What is CAR-T? How does it work? How is it being looked at in myeloma? Companies involved in this Application in AL amyloidosis? Regulatory challenges faced (e.g. cost, hospital provision etc) Role of advocacy in trying to make this available for patients Speaker: Dr. Michael Hudecek, University of Wuerzburg, Germany
11:15 – 11:30	Coffee break
11:30 – 12:30	AL amyloidosis clinical session – Updates in treatment of AL amyloidosis Chair: Lise-Lott Eriksson, Blodcancerförbundet Sweden Diagnostics Link between myeloma and AL amyloidosis Treatment of newly diagnosed AL amyloidosis (and updates from ASH) Treatment of relapse AL amyloidosis (and updates from ASH) Coordinated care in AL amyloidosis Upcoming treatments and clinical trials Speaker: Dr Moshe Gatt, Israel	Breakout Session Advocacy “Measuring and utilising quality of life” Chair: Kate Morgan, MPE PROMS, PREMS, PRO, QoL measures and patient Preference studies Examples in myeloma Examples in AL amyloidosis How they can be used in practice? Can they improve survival? Speaker: Jayne Galinsky, Myeloma UK
12:30 – 14:00	Lunch
14:00 – 16:15	ROTATING WORKSHOP SESSIONS (45 minutes each – Choose 2 out of 3, 15 min for rotation) Internal and external communications. How to create a communications strategy Speaker: Ana Vallejo, Myeloma Patients Europe Fundraising for patient groups Speaker: Michaela Geissler, Sarcoma Patients EuroNet Association (SPAEN) Reasonable Agreements between Patient Advocates and Pharmaceutical Companies Speaker: Jan Geissler, CML Advocates Network
16:15 – 16:45	Coffee Break
16:45 – 17:30	Supportive and psychosocial issues for myeloma and AL amyloidosis Chair: Ibolya Keri, MOHA, Hungary Psychosocial issues for patients (supportive care, emotional care etc) Speaker: Fatima Castaño, psycho-oncologist Communicating with patients Speaker: Diego Villalón, social worker, Fundación MÁS QUE IDEAS
19:30 – 22:00	Offsite dinner in Munich

Sunday, 17 March

8:30 – 10:45	General Assembly (for MPE members only)
11:15 – 11:450	Coffee break
11:45 – 13:00	General Assembly (for MPE members only)
13:00 – 14:00	Farewell lunch

For questions, please contact the MPE AGM team at .

Back to Anual Masterclass AGM

AGM 2019 Agenda

Find below the final agenda for the MPE Annual General Meeting 2019.

Friday, 15 March 2019

13:00 – 15:00
Check-in and registration
Lunch at the hotel restaurant “Bistro”

15:00 – 15:10
Welcome & Introductions
Hans Scheurer – President MPE
Ananda Plate – CEO MPE

15:10 – 16.10
Myeloma Treatment Updates
Chair: Riikka-Leena Manninen, MPE Board Member

Treatment of newly diagnosed myeloma
Role of maintenance treatment
New and upcoming treatments for NDMM
Updates on treatment of relapsed myeloma
New and upcoming treatments for relapsed MM
Update on related conditions (myeloma, AL amyloidosis etc)

Speaker: Prof. Heinz Ludwig, Wilhelminen Cancer Research Institute, Austria

16:10 – 17:00

Spotlight on MPE scholarship programme

Chair: Kate Morgan, MPE & Ana Vallejo, MPE
Myeloma UK (UK) – Research Capacity Building Workshops, Jayne Galinsky
Blodkreftforeningen (Norway) – Workshop on patient involvement in myeloma research, Jacob Hygen
Kraujas (Lithuania) – Myeloma infoday and the book “Sexuality and oncological diseases”, Aistė Strelčiūnė
Blodcancerförbundet Sweden (Sweden) – Workshop on combination therapy in myeloma, Lise-Lott Eriksson
Borka (Macedonia) – Myeloma campaign “Let’s make changes”, Biba Dodeva

17:00 – 17:15

Coffee break

17:15 – 19:00

Plenary Workshop AL Amyloidosis
Chair: Ananda Plate and Hans Scheurer, MPE
Introduction to AL amyloidosis (20 min)
Speaker: Dr Moshe Gatt, Israel

AL amyloidosis from a patient advocates view (10 min.)
Speaker: Daniel Drimer, Amyloidosis Israel

Challenges of diagnosing myeloma from the patient advocates view (10 min.)Speaker: Varda Shoham, Myeloma Israel

Workshop (40 min. team work in small groups and 20 minutes for discussion/feedback)

How can the AL amyloidosis and myeloma community collaborate to help build a stronger AL amyloidosis community in Europe?
What does the picture of diagnosing AL amyloidosis and myeloma look like in your country?
How can we tackle the issue of late diagnosis of AL amyloidosis and myeloma at national level?
What can MPE do to tackle the issue of late diagnosis of AL amyloidosis and myeloma at a Europe level?

20:00 – 22:00

Dinner (Hotel restaurant “Bistro”)

Saturday, 16 March 2019

9:00 – 10:00

Surrogate end-points and biomarkers in myeloma and AL amyloidosis
Chair: Ron Dloomy, MPE Board Member

Minimal residual disease in myeloma and AL amyloidosis
Biomarkers in myeloma and AL amyloidosis
Regulatory challenges associated with these and getting new medicines approved

Speaker: Dr. Moshe Gatt, Israel

10:00 – 10:15

Coffee break

10:15 – 11:15

The role of CAR-T – Room: Sapporo/Harrare
Chair: Roman Slomkowski, MPE Board Member

What is CAR-T?
How does it work?
How is it being looked at in myeloma?
Companies involved in this
Application in AL amyloidosis?
Regulatory challenges faced (e.g. cost, hospital provision etc)
Role of advocacy in trying to make this available for patients

Speaker: Dr. Michael Hudecek, University of Wuerzburg, Germany

11:15 – 11:30

Coffee break

11:30 – 12:30

AL amyloidosis clinical session – Updates in treatment of AL amyloidosis
Chair: Lise-Lott Eriksson, Blodcancerförbundet Sweden

Diagnostics
Link between myeloma and AL amyloidosis
Treatment of newly diagnosed AL amyloidosis (and updates from ASH)
Treatment of relapse AL amyloidosis (and updates from ASH)
Coordinated care in AL amyloidosis
Upcoming treatments and clinical trials

Speaker: Dr Moshe Gatt, Israel

Breakout Session Advocacy
“Measuring and utilising quality of life”
Chair: Kate Morgan, MPE

PROMS, PREMS, PRO, QoL measures and patient
Preference studies
Examples in myeloma
Examples in AL amyloidosis
How they can be used in practice?
Can they improve survival?

Speaker: Jayne Galinsky, Myeloma UK

12:30 – 14:00

Lunch

14:00 – 16:15

ROTATING WORKSHOP SESSIONS
(45 minutes each – Choose 2 out of 3, 15 min for rotation)

Internal and external communications. How to create a communications strategy
Speaker: Ana Vallejo, Myeloma Patients Europe
Fundraising for patient groups
Speaker: Michaela Geissler, Sarcoma Patients EuroNet Association (SPAEN)
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies
Speaker: Jan Geissler, CML Advocates Network

16:15 – 16:45

Coffee Break

16:45 – 17:30

Supportive and psychosocial issues for myeloma and AL amyloidosis
Chair: Ibolya Keri, MOHA, Hungary

Psychosocial issues for patients (supportive care, emotional care etc)
Speaker: Fatima Castaño, psycho-oncologist
Communicating with patients
Speaker: Diego Villalón, social worker, Fundación MÁS QUE IDEAS

19:30 – 22:00

Offsite dinner in Munich

Sunday, 17 March

8:30 – 10:45

General Assembly (for MPE members only)

11:15 – 11:450

Coffee break

11:45 – 13:00

General Assembly (for MPE members only)

13:00 – 14:00

Farewell lunch

For questions, please contact the MPE AGM team at .

Subscribe to

our newsletter!

Subscribe here